Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
The goal of this study is to evaluate whether fruquintinib(HMPL-013) plus sintilimab(IBI308) is safe and effective in the treatment of advanced endometrial cancer(EMC).
Advanced Endometrial Cancer
DRUG: fruquintinib|BIOLOGICAL: sintilimab|DRUG: paclitaxel|DRUG: doxorubicin
Progression-Free Survival (PFS) as assessed by IRC, Progression-free survival (PFS) is defined as the time from randomization to disease progression assessed by IRC or death due to any cause, whichever occurs first., Up to approximately 4 years|Overall Survival (OS), Overall Survival (OS) is defined as the time from randomization to death due to any cause., Up to approximately 4 years
Objective Response Rate (ORR), Objective Response Rate (ORR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR) , as assessed by IRC and investigator., Up to approximately 4 years|Duration of Response (DoR), For patients who reached complete response (CR) or partial response (PR), Duration of Response (DoR) is defined as the time from the first CR or PR until disease progression or death due to any cause, whichever occurs first ,as assessed by IRC and investigator., Up to approximately 4 years|Disease Control Rate (DCR), Disease Control Rate (DCR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR) or maintained a stable disease, as assessed by IRC and investigator., Up to approximately 4 years|Time To Response (TTR), Time To Response (TTR) is defined as the time from the start of treatment to the first objective response rate (ORR) ,as assessed by IRC and investigator., Up to approximately 4 years|Progression-Free Survival (PFS) as assessed by investigator, Progression-Free Survival is defined as the time from randomization to disease progression assessed by investigator or death due to any cause, whichever occurs first., Up to approximately 4 years|Incidence and severity of Treatment-emergent Adverse Events (TEAE), Adverse events classified according to NCI CTCAE version 5.0, Up to approximately 4 years|Blood concentration of fruquintinib, Steady-state blood concentration of fruquintinib, At the end of cycle 4 day 14 (each cycle is 21 days)|Health-related quality of life (using EORTC QLQ-C30), Changes in EORTC QLQ-C30(European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30) scores from baseline, Up to approximately 4 years|Health-related quality of life (using EORTC QLQ-EN24), Changes in EORTC QLQ-EN24 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module) scores from baseline, Up to approximately 4 years
A randomized, open, positive-controlled, multicenter Phase III clinical study to compare the efficacy and safety of fruquintinib(HMPL-013) plus sintilimab(IBI308) versus chemotherapy in patients with advanced endometrial cancer who have progressed after first-line standard chemotherapy